New antibody drug takes aim at Hard-to-Treat brain lymphoma

NCT ID NCT05485753

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called GNC-038 in 7 people with relapsed or refractory central nervous system lymphoma (lymphoma that has spread to the brain or spine). The drug is a tetra-specific antibody designed to target cancer cells. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Because it's a small, early study, it's too soon to know if it will work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNC-038 (a tetra-specific antibody given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat central nervous system lymphoma.
What could go wrong: This is a very early, small trial (only 7 participants) focused on safety and dosing, not yet on effectiveness. The drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Beijing GoBroad Boren Hospital

Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.